John O. Mascarenhas

Oncology

1470 Madison Ave Fl 3
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 299 publications

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 30, 2026

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Journal: Expert review of hematology

Published: June 19, 2026

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

Journal: Leukemia

Published: June 08, 2026

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

Interferon in early MF: intersection of biology and evidence.

Interferon in early MF: intersection of biology and evidence.

Journal: Blood advances

Published: May 29, 2026

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Journal: Leukemia & lymphoma

Published: May 18, 2026

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Journal: Blood advances

Published: May 18, 2026

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Journal: Lancet regional health. Americas

Published: March 25, 2026

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Journal: Leukemia

Published: March 20, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)

Published: March 07, 2026

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 27, 2026

Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1.

Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1.

Journal: Case reports in hematology

Published: February 09, 2026

Showing 1-12 of 299

Last Updated: 09/26/2026